{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:01:51Z","timestamp":1776142911279,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T00:00:00Z","timestamp":1523059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00228-018-2458-9","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T13:34:26Z","timestamp":1523108066000},"page":"931-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters"],"prefix":"10.1007","volume":"74","author":[{"given":"Takayuki","family":"Katsube","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Hernandez-Illas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Wajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,7]]},"reference":[{"key":"2458_CR1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","volume":"71","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y (2016) In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother 71:670\u2013677","journal-title":"J Antimicrob Chemother"},{"key":"2458_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2015","unstructured":"Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y (2015) In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729\u2013734","journal-title":"Antimicrob Agents Chemother"},{"key":"2458_CR3","doi-asserted-by":"publisher","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","volume":"61","author":"S Matsumoto","year":"2017","unstructured":"Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, Tsuji M, Yamano Y (2017) Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother 61:e00700\u2013e00717","journal-title":"Antimicrob Agents Chemother"},{"key":"2458_CR4","doi-asserted-by":"crossref","unstructured":"Portsmouth S, Veenhuyzen D, Echols R, Machida M, Arjona Ferreira JC, Ariyasu M, Nagata T (2017) Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), abstr ECCMD-7582. Cefiderocol Compared with Imipenem\/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)","DOI":"10.1093\/ofid\/ofx163.1399"},{"key":"2458_CR5","doi-asserted-by":"publisher","first-page":"e02163","DOI":"10.1128\/AAC.02163-17","volume":"62","author":"Y Saisho","year":"2018","unstructured":"Saisho Y, Katsube T, White S, Fukase H, Shimada J (2018) Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative Bacteria, in healthy subjects. Antimicrob Agents Chemother 62:e02163\u2013e02117","journal-title":"Antimicrob Agents Chemother"},{"key":"2458_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","volume":"57","author":"T Katsube","year":"2017","unstructured":"Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C (2017) Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584\u2013591","journal-title":"J Clin Pharmacol"},{"key":"2458_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism\/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815\u2013832","journal-title":"Drug Metab Dispos"},{"key":"2458_CR8","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2017) In vitro metabolism- and transporter-mediated drug-drug interaction studies"},{"key":"2458_CR9","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2017) Clinical drug interaction studies\u2014study design, data analysis, and clinical implications"},{"key":"2458_CR10","unstructured":"European Medicines Agency (2012) Guideline on the investigation of drug interactions"},{"key":"2458_CR11","unstructured":"FDA, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). ZERBAXA. Application Number: 206829Orig1s000"},{"key":"2458_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40262-014-0161-2","volume":"53","author":"S Johansson","year":"2014","unstructured":"Johansson S, Read J, Oliver S, Steinberg M, Li Y, Lisbon E, Mathews D, Leese PT, Martin P (2014) Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. Clin Pharmacokinet 53:837\u2013847","journal-title":"Clin Pharmacokinet"},{"key":"2458_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","volume":"51","author":"AJ Busti","year":"2008","unstructured":"Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R (2008) Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51:605\u2013610","journal-title":"J Cardiovasc Pharmacol"},{"key":"2458_CR14","unstructured":"Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. 1995. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 39:692\u2013695"},{"key":"2458_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40262-015-0270-6","volume":"54","author":"TB Stage","year":"2015","unstructured":"Stage TB, Br\u00f8sen K, Christensen MM (2015) A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet 54:811\u2013824","journal-title":"Clin Pharmacokinet"},{"key":"2458_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","volume":"76","author":"SG Simonson","year":"2004","unstructured":"Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167\u2013177","journal-title":"Clin Pharmacol Ther"},{"key":"2458_CR17","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","volume":"8","author":"KA Kellick","year":"2014","unstructured":"Kellick KA, Bottorff M, Toth PP (2014) A clinician\u2019s guide to statin drug-drug interactions. J Clin Lipidol 8:S30\u2013S46","journal-title":"J Clin Lipidol"},{"key":"2458_CR18","doi-asserted-by":"crossref","unstructured":"Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R (2017) Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 61:e01381-16, e01381, e01316","DOI":"10.1128\/AAC.01381-16"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2458-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T13:53:29Z","timestamp":1571061209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2458-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2458"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2458-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,7]]},"assertion":[{"value":"28 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Takayuki Katsube, Shiro Miyazaki, Yukitoshi Narukawa, and Toshihiro Wajima are employees of Shionogi. Martha Hernandez-Illas conducted this research at QPS Miami Research Associates, LLC (South Miami, FL, USA) in the course of their employment, and their employers were compensated by Shionogi for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted at QPS Miami Research Associates, South Miami, FL, in accordance with all appropriate regulatory requirements and under the protocol approved by an institutional review board, IntegReview IRB, Austin, TX. This study was conducted in accordance with current International Council for Harmonization (ICH) Good Clinical Practices (GCP), all appropriate subject privacy requirements, and the ethical principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Prior to enrollment, subjects received a full explanation of the nature and the objectives of the study, the safety of the drugs under investigation, and that they were free to withdraw from the study at any time without prejudice. Prior to the initiation of any study related procedures the subjects provided written informed consent and received a copy of the signed consent form to keep as a reference.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}